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Abstract
MicroRNAs represent a class of small RNAs derived from polymerase II
controlled transcriptional regions. The primary transcript forms one or several
bulging double stranded hairpins which are processed by Drosha and Dicer
into hetero-duplexes. The targeting microRNA strand of the duplex is
incorporated into the RNA Induced Silencing Complex from where it silences
up to hundreds of mRNA transcript by inducing mRNA degradation or blocking
protein translation. Apart from involvement in a variety of biological processes,
microRNAs were early recognized for their potential in disease diagnostics and
therapeutics. Due to their stability, microRNAs could be used as biomarkers.
Currently, there are microRNA panels helping physicians determining the
origins of cancer in disseminated tumors. The development of microRNA
therapeutics has proved more challenging mainly due to delivery issues.
However, one drug is already in clinical trials and several more await entering
clinical phases. This review summarizes what has been recognized
pre-clinically and clinically on diagnostic microRNAs. In addition, it highlights
individual microRNA drugs in running platforms driven by four leading
microRNA-therapeutic companies.
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Two decades have passed since the groundbreaking work from 
the laboratories of Gary Ruvkun and Victor Ambros, which dem-
onstrated that a small temporal non-coding RNA could influence 
development of Caenorhabditis elegans by base pairing to the 3´ 
untranslated region (3´ UTR) of a coding messenger RNA (mRNA) 
thereby regulating its translation1,2. For several years these RNA 
molecules were considered to be specific to C. elegans. A final 
recognition that they also played this role in additional systems, 
including human cells, marked the official birth of microRNAs 
(miRNAs)3–5.
miRNAs are separated from other small RNAs by the prediction of 
a hairpin fold-back structure from the precursor transcript together 
with expression evidence of an approximately 22 nucleotide-long 
mature sequence. Currently, 1600 human miRNA precursors have 
been deposited into miRBase v19 based on analyses of RNA deep-
sequencing data6. The nomenclature of these miRNAs is based on 
a “mir” or “miR” prefix with identifying numbers assigned sequen-
tially at the time of discovery. “mir” denotes a precursor miRNA 
whereas “miR” denotes a mature miRNA sequence. A precursor 
miRNA can give rise to one or two mature miRNAs. Similar or 
identical sequences can be given the same number. Distinction is 
then accomplished by a letter (similar sequences) or numeral end-
ing (identical sequences). For example, miR-15a and miR-15b have 
identical 5´ ends but differ by four nucleotides in their 3´ regions. 
In contrast, miR-16-1 and miR-16-2 are identical but encoded on 
two separate chromosomes, chromosome 13 and 3, respectively7 
miRBase v19.
Genomic location and transcription of microRNAs
miRNA genes reside either in intergenic regions, within introns of 
coding or non-coding genes or within exons of non-coding genes8. 
Approximately one third of miRNAs are intergenic and about 
one third of all miRNA genomic loci contain clustered miRNAs   
miRBase v19. Work from the laboratory of David Bartel and others 
demonstrated that miRNAs that are oriented in the same genomic 
orientation and separated by less than 50 kb but more than 0.1 kb 
are highly correlated in their expression patterns. These results sug-
gest that they originated from a miRNA cluster producing polycis-
tronic transcripts9,10. Consistent with this, the laboratory of David 
Fisher showed that intronic miRNAs with independent transcrip-
tional start sites were located substantially further away from their 
host gene start site, displaying a median distance of 57 kb11. Pre-
dicting the number of human miRNA clusters and miRNA precur-
sor transcripts using such cutoffs in miRBase generates 175 and 
538, respectively.
The majority of miRNAs are transcribed as long primary transcripts 
by RNA polymerase II and many are capped and polyadenylated12,13. 
Analysis of miRNAs residing in intergenic primary transcripts   
indicates that such transcripts are shorter than protein-coding tran-
scripts with transcriptional start sites about 2 kb upstream of the 
pre-miRNA and polyadenylation signals 2 kb downstream14. A sub-
set of miRNAs is transcribed by RNA polymerase III. This cluster 
of miRNAs is located among Alu rich regions on chromosome 1915.
While most intronic miRNAs seem to be expressed from their   
host-gene transcriptional machinery, promoters and transcriptional 
activators of intergenic miRNAs are poorly defined. In order to 
identify miRNA promoters and their transcription factors in stem 
cells, the laboratory of Richard Young set up a score system. This 
system overlaid genomic coordinates of tri-methylated Lysine 
4 of Histone 3 (H3K4me3), their proximity to annotated miRNA 
sequences, expression sequence tag (EST) data and conservation 
between species with genome-wide association of transcription fac-
tors Oct4, Sox2, Nanog and Tcf3. The results demonstrated that 
miRNAs are regulated by Oct4, Sox2, Nanog and Tcf3 to the same 
degree as protein-coding genes16. These findings suggest that most 
miRNAs are transcriptionally regulated in a “protein-coding like” 
fashion.
Processing of microRNAs
Primary miRNA transcripts (pri-miRNAs) form hairpin bulges due 
to sequence complementarity. These hairpins are subject to pro-
cessing by the Microprocessor complex which takes place in the 
nucleus20. The Microprocessor consists of the RNase III enzyme 
Drosha and its partner DiGeorge syndrome critical region gene 8 
(DGCR8). Upon binding of DGCR8 to pri-miRNA at the junction 
of single-stranded to double-stranded RNA, Drosha cuts the pri-
miRNA hairpin 11 bp into its double-stranded stem sequence gen-
erating slightly smaller hairpins known as pre-miRNAs. Intronic 
miRNAs are cleaved by Drosha co-transcriptionally preceding 
splicing of the primary transcript17. Pre-miRNAs are exported into 
the cytoplasm by the exportin 5 Ran-GTP complex where they are 
released by GTP hydrolysis and further processed by the RNase III 
Dicer into an approximate 22 nucleotide duplex. Dicer counts 22 
nucleotides from the 5´ end of the pre-miRNA before cleaving, gen-
erating a duplex with 3´ end overhangs at each side. RNA helicases 
facilitate unwinding of the duplex with one strand being incorpo-
rated into the targeting miRNA containing RNA Induced Silencing 
Complex (RISC) together with the Argonaute protein. Thermosta-
bility of the 5´ ends determines that the strand will be incorporated 
in the complex and that the strand is left out will be degraded8,18.
MicroRNA functional targeting
The miRNA-RISC complex binds to 3´ UTRs of mRNAs via nucleo-
tide complementarity. Upon binding, it either induces mRNA deg-
radation or inhibits protein translation. It is unclear to what extent 
mRNA degradation and translational inhibition coincide, but steady 
state levels suggest that mRNA degradation serves as the major 
final outcome for miRNA targeted transcripts19. Although bind-
ing can occur in 5´ UTRs and open reading frames, targeting in 
these regions are less frequent and efficient compared to 3´ UTR 
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demonstrated to target other RNA species, including long non cod-
ing RNAs (lncRNAs), antisense RNAs and competing endogenous 
RNAs21–23. These new layers of functional regulation may certainly 
add to the clinical value of miRNAs but a deeper description is out 
of scope for this review.
miRNAs bind their targets through seed- or seed-less pairing. The 
miRNA “seed” is located in its 5´ end and expands from nucleotides 
2–7. miRNAs that are interacting with their targets only through the 
seed region rarely produce efficient targeting. Additional base pair-
ing of either nucleotide one, eight or both results in canonical seed 
targeting referred to as “7mers” or “8mers” correlating with func-
tional outcomes. Disrupted complementarity at any of the nucleo-
tides two to seven leads to seed-less targeting. Seed-less targeting 
depend on compensatory complementarity along the mature miRNA 
sequence. In contrast, canonical seed targeting may be functional 
without such additional binding20. Interestingly, a recent paper map-
ping the human miRNA-mRNA interactome suggests that 60% of 
seed interactions are non-canonical24. During recent years, a num-
ber of prediction algorithms have been developed to track miRNA 
targeting based on seed pairing, overall complementarity, pairing 
stability, target site evolutionary conservation and UTR context20.
Generally, a single miRNA is predicted to have hundreds of targets. 
Prediction algorithms provide significant information for selecting 
appropriate miRNAs for targets of interest but there are several short-
comings when one seeks the biological outcome of a specific miRNA. 
First, expression levels of many miRNAs vary greatly between dif-
ferent cell types/tissues or disease states10,25, and this affects the 
stoichiometry of the binding of the miRNA to the target, potentially 
altering its impact. Secondly, the targeting capacity of a certain miRNA 
can be blunted by the state of its target, for example, shortened 3´ 
UTRs in cancer cells or point-mutations in the 3´ UTRs26,27.
The effect of a given miRNA may not necessarily correlate with 
repression of its targets. 3´ UTRs vary greatly in size, with many 
harboring binding sites for numerous endogenous miRNAs20,26. Inhib-
iting a single miRNA is therefore likely to give non-detectable or 
very modest derepression of an investigated target. Finally, func-
tional assays demonstrating mRNA or protein alterations preceded 
by the introduction of ‘mimic miRNAs’ or inhibiting endogenous 
miRNAs could stem from the execution of indirect biological pro-
grams and not necessarily reflect miRNA-to-target interaction.
To combat such issues, miRNA researchers have turned to bio-
chemical methods. Pull-down assays for either the miRNA itself or 
the RISC-complex followed by RT-PCR, microarray or sequencing 
could determine if the physical interaction between a given miRNA/
mRNA is present or not28–30. By combining biochemical approaches 
with functional assays, it is possible to build confidence in specific 
miRNA targets. Given the huge number of predicted targets for any 
given miRNA, it is plausible to assume that only a fraction of pre-
dicted targets are substantially affected31,32. Interestingly, a recent 
study overlaid interacting transcripts with the targets that were sig-
nificantly downregulated due to exogenous expression of a mimic 
miRNA in two different cell lines. They observed that the majority 
of miRNA to transcript interactions may result in no or very weak 
functional outcomes29. Such combinatory approaches are likely to 
be crucial in order to fully dissect miRNA functional targeting and 
they may ease biological network analyses by substantially reduc-
ing the number of targets.
MicroRNAs in disease diagnostics
Observations that miRNAs displayed high stability in paraffin- 
embedded tissues from clinical samples or in human plasma33,34 
raised the possibility that miRNA expression analysis may be a 
useful tool to define disease states. An early key report from the 
laboratory of Todd Golub covering 217 mammalian miRNAs and 
several hundred samples, including clinical samples, common can-
cer cell lines and mouse tumors, demonstrated that miRNA profiles 
could distinguish a tumor’s developmental origin and that miRNAs 
are generally downregulated in cancers (129 out of 217 miRNAs). 
Interestingly, poorly differentiated tumors displayed lower miRNA 
expression compared to tumors with a higher differentiation25. This 
report was complemented by a study looking at miRNA expression 
profiles in human solid tumors35. miRNA signatures were further 
used to define subtypes of cancers, such as the distinction between 
basal and luminal breast cancers36,37. Sempere et al. showed that 
ER+PR+HER2+, ER-PR-HER2+ and ER-PR-HER2- breast cancer 
tumors exhibited distinct miRNA patterns with expression of miR-
205 in triple negative breast cancers correlating positively with clin-
ical outcome. Analysis of separate cancers demonstrated miRNA 
profiles could predict clinical progression38,39. miR-15a and miR-16-1 
act as prognostic biomarkers in chronic lymphocytic leukemia 
(CLL) and let-7a is a marker for lung cancers38,39. The laboratory of 
Tyler Jacks gave an ultimate support to the notion that the majority 
of miRNAs display lower expression in tumors and therefore may 
play tumor suppressive properties. By using conditional knockout 
mice for Dicer crossed with a K-Ras driven lung cancer model they 
demonstrated that a global reduction of miRNA biogenesis leads to 
reduced survival in affected mice40.
In addition to cancer, miRNA expression profiles could also be used 
to distinguish distinct forms of heart disease41, muscular disorders42 
and neurodegenerative diseases43. The human miRNA-associated 
disease database (HMDD) serves as a resource for scientists 
screening the constantly increasing number of miRNA profiles for 
a wide range of diseases44. At the time of writing this review, the 
HMDD-database covered disease-associations from 2741 scientific 
publications.
Circulating microRNAs
The vast majority of miRNA expression profile reports stem from 
solid tissues although miRNAs can be readily detected in human 
plasma, serum or total blood due to their small size and high stability35,45. 
The potential of circulating miRNAs as biomarkers in serum was 
indicated early by studies examining patients with diffuse large 
B-cell lymphoma, highlighting miR-21 as a potential biomarker46. 
Prostate cancer patients could be distinguished from healthy coun-
terparts by analyzing the expression level of miR-14335. These 
studies were followed by additional reports of miRNAs in breast 
cancer (using whole blood)47, colorectal cancer (using plasma)48 
and squamous cell lung cancer (using sputum)49 patients. Interest-
ingly, Boeri et al. demonstrated that circulating miRNAs may also 
be used for predicting purposes. They displayed miRNA signatures 
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onset of disease by analyzing expression in samples taken before 
diagnosis, at the time of detection by computed tomography and in 
disease-free smokers50.
In a massive undertaking Keller et al. analyzed 863 miRNAs from 
454 human blood samples. The samples were from patients suf-
fering from 14 separate diseases including lung cancer, prostate 
cancer, pancreatic ductal adenocarcinoma, melanoma, ovarian 
cancer, gastric tumors, Wilms tumor, pancreatic tumors, multi-
ple sclerosis, chronic obstructive pulmonary disease, sarcoidosis, 
periodontitis, pancreatitis and myocardial infarction. On average, 
more than 100 miRNAs were deregulated in the blood for each 
disease. By utilizing this data and developing mathematical algo-
rithms and probability plots the authors were able to accurately 
predict the disease in more than two thirds of individuals involved 
in the study51. It should be noted that miRNA patterns in blood are 
unlikely to be the same between different types of blood cells. Dis-
tinct hematopoietic lineages display different miRNA-profiles52, 
possibly suggesting that differences in expression in specific 
diseases are due to shifts in hematopoietic cell populations. This 
could be pronounced in diseases directly affecting the blood such 
as cancers spreading to the bone marrow or multiple sclerosis, a 
chronic central nervous system disease associated with an abnor-
mal immune system response. Using 27 distinct cell populations 
with the highest variance, Keller et al. computed that such shifts 
could account for a maximum of 60% of differences in the 
observed miRNA profiles51.
How are miRNAs released into the blood stream? Rechavi et al. 
demonstrated that synthetic miRNA mimics, viral miRNAs or endog-
enous miRNAs could be released from B-cells and taken up by 
T-cells upon cell contact53. Further, Pegtel et al. demonstrated secre-
tion of miRNAs from Epstein-Barr virus (EBV)-infected B-cells 
via exosomes, providing protection of the miRNA from RNases54 
and Yuan et al. reported the transfer of miRNAs from embryonic 
stem cells to fibroblasts via embryonic stem cell microvesicles55. 
Finally, Kosaka et al. demonstrated that miRNA secretion occurs in 
a ceramide-dependent fashion, which could be blunted by knocking 
down nSmase2, an enzyme required for ceramide biosynthesis56.
In addition to serum/plasma, the presence of miRNAs has also been 
demonstrated in urine57 and saliva58, with two miRNAs, miR-125a 
and miR-200a, displaying lower expression in patients with oral 
squamous cell carcinoma compared to healthy subjects59.
MicroRNA profiling methods
miRNA expression profiling and disease association studies are 
conducted using a set of different methods including miRNA micro-
array platforms, quantitative real-time polymerase chain reaction 
(qRT-PCR),  in situ hybridization and high throughput sequenc-
ing. Both qRT-PCR and hybridization methods are highly sensi-
tive and quantitative. This makes them useful for analyzing small 
sets of miRNAs60. It is worth noting that there are limitations with 
hybridization methods due to potential hybridization of the probe to 
pri-, pre- and mature miRNAs. Detection of mature miRNA sequences 
through qRT-PCR demands a stem-loop RT primer, specific prim-
ers for amplification of the cDNA and a TaqMan probe (Roche 
Molecular Diagnostics, Applied Biosystems)61. In situ hybridiza-
tion can either be represented by fluorescence in situ hybridization 
(FISH) or chromogenic in situ hybridization (CISH) and detection 
of miRNAs as well as other non-coding RNAs is possible without 
protease-treatment of tissues62.
For high-throughput studies, miRNAs are profiled using array plat-
forms or sequencing. Next-generation sequencing technologies offer 
lower costs and shorter processing time making this platform highly 
attractive. Today, researchers frequently use sequencing techniques 
to profile miRNA signatures in distinct sets of tissues/diseases.
Clinical microRNA diagnostics
A major challenge in clinical diagnostics is cancers with poor dif-
ferentiation. Even though these cancers account for only a few 
percent of malignancies, they display substantially distinct gene- 
signatures making it notoriously hard to trace the cell of origin 
despite the availability of the latest microRNA platforms63.
Perhaps the most exciting potential of miRNAs in current diag-
nostics started with a study comparing miRNA expression using 
miRNA microarrays in 205 primary versus 131 metastatic tumors 
covering 22 different tumor origins. The authors developed a binary 
decision tree classifier based on miRNA expression with tissues 
displaying the highest specificity of certain miRNAs placed at the 
top of the tree. Following this classifier, a remarkably low num-
ber of 48 miRNAs predicted tissue origin at close to 90% accuracy 
when tested on a blinded set64 (Table 1). This study, together with 
subsequent studies confirming the accuracy of using miRNAs as 
diagnostics for tumors of unknown origin65,66, was partly driven by 
the miRNA diagnostics company Rosetta Genomics, Israel.
Based on these reports, Rosetta Genomics is now offering a panel 
(miRview-mets2) to clinicians so that the origin of metastatic can-
cers can be identified where the primary origin of metastasis is 
questionable. The panel consists of a test of 64 miRNA biomarkers 
validated on 489 samples of which 146 represent metastatic tumors 
covering 42 tissues of origin67. In addition to the “miRview-mets2” 
panel, Rosetta Genomics also offers four additional clinical tests: 
“miRview-lung”, “miRview-squamous”, “miRview-meso” and 
“miRview-kidney”. MiRview-lung differentiates four types of pri-
mary lung cancer (small cell lung cancer, squamous non-small cell 
lung cancer (NSCLC), non-squamous NSCLC and carcinoid) using 
eight separate miRNA biomarkers68. MiRview-squamous separates 
non-small cell lung cancers (NSCLC) into squamous cell carci-
nomas and adenocarcinomas using a single miRNA, miR-20569. 
MiRview-meso defines samples into a mesothelioma or non- 
mesothelioma origin based on three separate miRNAs70 and miRview-
kidney separates kidney cancer into its four primary types (benign 
oncocytoma, clear cell renal carcinoma, papillary renal carcinoma 
and chromophobe renal carcinoma) using six miRNAs. All clinical 
panels rely on the same tree-classifier as in the original paper63,71.
The move of miRNA diagnostics into the clinics led by Rosetta 
Genomics and others may aid the use of personalized medicine in 
the treatment of cancers. Importantly, miRNA diagnostics are not 
just an additional approach for differentiated cancers but a potential 
breakthrough for cancers initially defined as of unknown origin.
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In addition to more well-established approaches of analyzing miRNA 
expression profiles, predisposition to certain cancer types may be 
predicted by the existence of single nucleotide polymorphisms 
(SNPs). SNPs can reside in either precursor miRNAs, mature miRNAs 
or in 3´ UTRs disrupting or creating miRNA binding sites72.
Screening of 42 miRNA expression profiles in chronic lymphocytic 
leukemia (CLL) revealed the presence of mutations in 5 miRNAs; 
all SNPs were detected in the pri- or pre-miRNA structure. For one 
of these, miR-16-1, a mutation in the precursor transcript led to a 
significant reduction in mature miRNA expression40. Other reports 
of SNP variants in miRNA precursors where the mutant variant cor-
relates with an increased risk of cancer include miR-196a-2 and 
miR-499 in breast cancer73, miR-196a-2 in head and neck cancer74, 
whilst increased mature levels of miR-146a can lead to an earlier 
onset of breast and ovarian cancers75. In addition, SNPs affect-
ing factors in the miRNA processing machinery lead to either an 
increased or reduced risk of renal cell carcinoma depending on 
factors which were affected76.
Examples of SNPs located in 3´ UTRs of miRNA target sites 
include the binding site of miR-221/222 and miR-146 in Kit77 as well 
as the let-7 binding site in the 3´ UTR of K-Ras. The latter displays 
an alteration associated with an increased risk of NSCLC28. Further, 
a SNP in the miR-184 binding site in the 3´ UTR of tumor necrosis 
factor alpha-induced protein 2 (TNFAIP2) resulted in an increased 
risk of squamous cell carcinoma of the head and neck78.
Using available SNP data from “The 1000 Genomes Project”79, 
Richardson et al. concluded that approximately 5% of all SNPs 
maps to miRNA recognition elements (MREs). Among these SNPs, 
22% associated with disease phenotype80. Interestingly, these num-
bers suggest that SNPs residing within MREs are likely to be under 
selective pressure.
MicroRNAs in therapeutics
The idea of using miRNAs in therapeutics is highly appealing after 
observing the outcomes from manipulating these molecules. Rather 
than intercepting a single target as in the case of selective protein 
inhibitors, miRNAs can modulate entire gene programs. Importantly, 
Table 1. Rosetta Genomics initial binary tree classifier consisting of 24 nodes giving rise to 25 
leaves or defined cancer types. Each node uses 1 to 5 miRNAs for classification. Nodes giving no 
defined cancer types make broader distinctions. For example, Node #3 distinguishes epithelial tissues 
from mixed origin. Table is adapted from Rosenfeld et al. 2008.
Node MicroRNAs used at node Defined cancer types at node
1 miR-122a, miR-200c Liver
2 miR-372 Testis
3 miR-200c, miR-181a, miR-205 –
4 miR-146a, miR-200a, miR-92a –
5 miR-142-3p, miR-509 Lymph node, Melanocytes
6 miR-92b, miR-9*, miR-124a Brain
7 miR-152, miR-130a Meninges
8 miR-205 Thymus (type B2)
9 miR-192, miR-21, miR-210, miR-34b –
10 miR-194, miR-382, miR-210 Lung-pleura, Kidney
11 miR-187, miR-29b Sarcoma, Gastro Intestinal Stromal Tumors
12 miR-145, miR-194, miR-205 –
13 miR-21, let-7e Lung (carcinoid)
14 let-7i, miR-29a Colon
15 miR-214, miR-19b, let-7i Stomach, Pancreas
16 miR-196a, miR-363, miR-31, miR-193a, miR-210 –
17 miR-27b, let-7i, miR-181b Breast, Prostate
18 miR-205, miR-141, miR-193b, miR-373 –
19 miR-106b, let-7i, miR-138 Thyroid
20 miR-10b, miR-375, miR-99a –
21 miR-205, miR-152 Lung, Bladder
22 miR-345, miR-29c, miR-182 Endometrium, Ovary
23 miR-192, miR-345 Thymus (type B3)
24 miR-182, miR-34a, miR-148b Lung (squamous), Head and Neck
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which should be less detrimental to healthy tissues. Given the notion 
of deregulation of these molecules in a wide range of diseases and 
the robust degree of accurate profiling, one would estimate the 
chances of mapping specific miRNAs for manipulation of a given 
disease with minimal side-effects to be fairly good.
miRNAs fall into the class of RNAi-based therapeutics, a concept 
that is not completely new, having given birth to more than 20 clini-
cal trials so far81, but unlike short interfering RNAs/short hairpin 
RNAs (siRNAs/shRNAs), which are designed to target a single 
transcript, modulation of miRNAs, will affect hundreds of tran-
scripts and so would potentially be capable of shutting down entire 
deregulated pathways. Of course, specific targeting of disease asso-
ciated transcripts is probably required since a completely random 
modulation of hundreds of transcripts would be too harmful for the 
patient. However, such issues can be relatively easily investigated 
from in vitro studies conducting genome-wide mRNA expression 
together with pathway enrichment analysis. To date there is only 
one miRNA drug in clinical trials (SPC3649: inhibitor/antagomir 
of miR-122, Santaris Pharma, Denmark) (Figure 1). The slow pro-
gress stems from the general technical challenges with RNAi-based 
therapeutics including delivery, stability and avoidance of activat-
ing immune responses.
As discussed earlier in this review, endogenous miRNAs remain 
highly stable even when secreted into circulation. They resist   
nucleases by being enclosed into microvesicles or exosomes. Creat-
ing complex delivery-vehicles for miRNA therapeutics is feasible 
but could be time-consuming and costly. To minimize stability 
issues, a range of chemical modifications have been developed 
for siRNAs, modifications likely to be transferrable to miRNAs 
due to their similar structures. These include Phosphorothioate,   
2´-O-methyl RNA, 2´-Fluoro-RNA and 2´O-methoxy-ethyl RNA, 
all of which provide greater nuclease resistance81,82. A phosphoro-
thioate modification exchanges a nonbridging oxygen atom with a 
sulfur atom at the phospho-backbone of the unmodified RNA. In 
addition to providing nuclease resistance this also promotes RNase 
H-mediated cleavage of targeted transcripts. The 2´O-methyl mod-
ification adds a methyl group (-CH3) to the second carbon of the 
ribose. Likewise, 2´Fluoro adds a fluorine atom at this position 
and 2´O-methoxy-ethyl adds a methoxy-ethyl group (-C3H7O). All 
2´-modifications increase Watson-Crick base pairing to targeted 
transcripts and substantiate nuclease resistance due to closer prox-
imity between the 2´ group and 3´ phospho-group. In addition, a 
modification known as locked nucleic acid (LNA) is widely used 
in synthesis for miRNA inhibiting drugs, sometimes referred as 
antagomirs. This modification utilizes a bridge between the 2´O 
group and 4´ carbon atom also referred to as 2´O-4´C-methylene 
linked ribonucleotides82.
Even though siRNAs, and in a similar way miRNA mimics, can be 
stabilized through chemical modifications, their size still demands 
complex vehicles in order to ensure delivery to different tissues   
in vivo83. In contrast, miRNA inhibiting drugs, or antagomirs, can 
be synthesized as short single-stranded oligonucleotides, their small 
size together with their potency/stability provided by the LNA-
modifications make delivery possible without vehicle-systems. For 
the rest of this review we will summarize miRNA drugs currently in 
clinical trials or likely to enter clinical trials in the near future. We 
bring up the platforms of four leading miRNA therapeutic compa-
nies of which three utilize the antagomir technique.
Miravirsen (Santaris Pharma)
Miravirsen (or SPC3649) is a LNA-modified oligonucleotide   
designed to inhibit miR-122 developed by Danish firm Santaris   
Figure 1. Leading companies developing microRNA therapeutics. The four stages at the top denote the progress of individual miRNA 
drugs. Red colored miRNAs indicate replacement therapy with drug mimicking the endogenous miRNA. Blue colored miRNAs indicate 
inhibition therapy with drug targeting the endogenous miRNA. *Santaris Pharma has completed two Phase I clinical trials and is currently in 
Phase II with their miR-122 targeting drug miravirsen.
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accounts for more than 70% of all miRNAs in the liver and has been 
shown to be crucial for the functional infection of Hepatitis C virus 
(HCV). The exact mechanism of how this miRNA facilitates viral 
replication is not clearly understood. It is suggested that interaction 
between miR-122 and two seed-sites in the 5´ noncoding region of 
HCV induces viral transcripts, giving this miRNA a non-classical 
function of inducing rather than inhibiting the function of its target85.
Treatment of chronic Hepatitis C-infected chimpanzees with mira-
virsen led to suppression of HCV without any obvious side-effects. 
Further, liver transcriptome analysis revealed 259 mRNAs containing 
full 8mer-seed miR-122 predicted binding sites to display increased 
expression following treatment, thus indicating such transcripts to 
be targeted by endogenous miR-122 in Hepatitis C. It is likely that 
some of those transcripts play additional therapeutic roles. Total 
serum cholesterol was reduced with downregulation of cholesterol 
metabolism genes84.
Since reporting their non-human primate study, miravirsen has 
gone through two phase I clinical trials, successfully proving that 
the drug is safe even in humans (NCT00688012, NCT00979927), 
and a Phase IIa clinical trial (NCT01200420) (Figure 1). This 
Phase IIa trial enrolled 38 patients with treatment-naïve chronic 
HCV infection to monitor safety, tolerability, pharmacokinetics 
and efficacy on HCV viral titer. Multiple dosage of miravirsen   
administered subcutaneously to patients gave promising outcomes 
with a mean reduction of HCV RNA levels by two to three loga-
rithmic levels. Further, almost half of the patients treated by the 
highest dose displayed undetectable levels of HCV RNA within 
4 weeks. These results are encouraging and highlight miravirsen 
as a potential future replacement therapy for patients with chronic 
HCV infection.
Discovering the general potential of miRNA inhibitory therapeutics 
using LNA-based or similar platforms for a wide range of diseases 
is a major task for the future. One might imagine that the tissue 
specificity of miR-122, its high abundance in this tissue compared 
to other miRNAs and the general convenience of delivering drugs 
systemically to the liver makes inhibition in this case easier than 
most other miRNAs. Despite such possible concerns, the devel-
opment of miravirsen by Santaris Pharma provides a landmark   
breakthrough for miRNA based therapeutics.
Anti-miRs (Regulus Therapeutics)
Regulus Therapeutics is a San Diego based company with a wide-
range program focusing on targeting endogenous miRNAs through 
inhibitory oligonucleotides in hepatocellular carcinoma, kidney   
fibrosis, atherosclerosis, HCV infection and glioblastoma. To keep 
such a platform running, Regulus has partnered with the corpo-
rate giants Sanofi, GlaxoSmithKline and AstraZeneca. In 2010, 
Regulus signed a deal with GlaxoSmithKline for the development 
of a  miR-122 inhibitor drug, thus providing direct competition with 
Santaris Pharma (see above).
None of Regulus’ programs have reached clinical phases but sub-
stantial preclinical work has been completed including a non- 
human primate study of inhibiting miR-33a/b for the treatment of 
atherosclerosis86 (Figure 1). miR-33b and miR-33a are encoded in 
the introns of the transcription factor loci SREBP1 and SREBP2, 
respectively, and are involved in the regulation of cholesterol and 
fatty acid homeostasis. This puts them as potential targets for 
treatment of cardiovascular diseases86. By treating African Green 
monkeys subcutaneously with 2´-fluoro-methoxyethyl-phosphoro-
thioate modified antisense-miR-33 oligonucleotides (anti-miR-33), 
the study demonstrated a decrease in very-low-density lipoprotein 
(VLDL)-triglycerides and an increase in high-density lipoprotein 
(HDL)86. Mechanistically, there was a significantly reduced repres-
sion of miR-33 predicted target genes and primates went through 
treatment without displaying significant side-effects86.
Using another anti-miR (anti-miR-21), Regulus convincingly dem-
onstrated that their technology could be used for the inhibition of 
migration/invasion of glioma in mice87, attenuating cardiac dys-
function in a mouse model of cardiac disease88 and executing an anti- 
fibrotic response in mice exposed to kidney injury89. Results from 
additional mouse-models exposed to Regulus-developed anti-miRs 
include suppression of lung-metastasis originating from breast 
tumors (anti-miR-10b)90, inhibition of neuroblastoma (anti-miR-
380-5p)91, antagonizing liver metastasis sourcing from melanoma 
(anti-miR-182)92 and improved glucose homeostasis and insulin 
sensitivity (anti-miR-103/107)93 (Figure 1).
MicroRNA replacement therapy, MRX34 (Mirna Therapeutics)
In contrast to the companies described above, Mirna Therapeutics 
is not focusing their platform around the inhibition of endogenous 
miRNAs but instead on introducing synthetic miRNA mimics as 
replacement therapies. The idea is to restore expression of certain 
miRNAs in tumors to a comparable level to surrounding healthy 
tissues. The platform of Mirna Therapeutics consists of eight drug 
candidates, solely focused on addressing tumor suppressive roles of 
miRNAs. Three out of eight candidate mimics represent miRNAs 
demonstrated by numerous publications to display tumor suppres-
sive properties (miR-34, let-7 and miR-16). Their lead candidate, 
MRX34, a miR-34a mimic compound, will probably be the first 
miRNA replacement compound to reach clinical trials (Figure 1). 
At the time of writing this review, Mirna Therapeutics is recruiting 
participants to a Phase I study of MRX34 (NCT01829971).
miR-34a represents one of the most documented tumor suppression- 
associated miRNAs, being a transcriptional product of the tran-
scription factor and genome guardian p5394. Pre-clinical work by 
Mirna Therapeutics has demonstrated potent anti-tumor effects 
by introducing miR-34a mimics into a variety of mice cancer 
models95,96.
The usage of miRNA mimics for systemic delivery is challenging 
compared to anti-miR drugs. miRNA mimics need to be double-
stranded in order to be processed correctly by the cellular RNAi- 
machinery and therefore cannot be administered “naked”. Successful 
delivery therefore requires complex delivery vehicles mimicking 
physiological settings where miRNAs reside in microvesicles or 
exosomes. For MRX34, Mirna therapeutics has developed cus-
tom nanoparticle liposomes. According to company information 
(MIRNA THERAPEUTICS) these liposomes increase stability, 
enhance delivery and prevent immune response effects. Extensive 
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carcinoma using liposomes provided promising outcomes and the 
upcoming clinical trial is recruiting patients with non resectable 
primary liver cancer or metastatic cancer with liver involvement 
(NCT01829971).
Anti-miRs (miRagen Therapeutics)
miRagen Therapeutics is an American company founded in 2007 
for the development of miRNA based drugs treating cardiac and 
muscular diseases. A partner alliance with Danish Santaris Pharma 
gives miRagen commercial rights to the LNA-based technique 
developed by Santaris. miRagen has programs covering both anti-
miR and miRNA mimics. The anti-miR program contains candidate 
drugs relatively close to clinical stages (Figure 1). This platform 
includes three drugs: MGN-9103, MGN-1374 and MGN-4893.
The lead drug, MGN-9103, targets miR-208 with implications for 
the treatment of chronic heart failure. miR-208 is a heart specific 
miRNA located in an intron of the alphaMHC gene, which has 
been demonstrated to be required for cardiac hypertrophy, myosin 
switching and fibrosis in response to stress97. Such cardiac remod-
eling was blocked by treating rats subcutaneously with LNA-based 
anti-miR-208 during hypertension induced heart failure98. Interest-
ingly, MGN-9103 was also recently suggested to play beneficial 
roles in a mouse model of diabetes/obesity99.
MGN-1374 targets miR-15 and miR-195, miRNAs shown to be 
upregulated in mouse hearts shortly after birth. Upregulation of 
miR-15 and miR-195 executes a postnatal cell cycle arrest during 
the process of heart regeneration after myocardial infarction100. 
By inhibiting these miRNAs using their LNA-based MGN-1374, 
miRagen enables post-myocardial infarction remodeling. Such   
remodeling enhanced heart function and induced cardiomyocyte 
proliferation in mice and pigs101.
MGN-4893, targets miR-451, a miRNA required for the expan-
sion of red blood cells. Inhibition of miR-451 in mice using anti-
miR-451 blocked erythrocyte differentiation suggesting that such 
inhibitors could be useful for the treatment of disorders leading to 
abnormal red blood cell production such as polycythemia vera102.
Concluding remarks
MicroRNAs have come a long way since the initial discoveries two 
decades ago. Their emerging potential as biomarkers in clinical 
diagnostics as well as modulators for the treatment of a variety of 
diseases is truly exciting. In the near future it will become clearer 
as to whether they have the power to become established as new 
molecular diagnostic benchmarks and whether microRNA-based 
therapy can compete with that of selective protein inhibitors.
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    Current Referee Status:
Referee Responses for Version 2
  Gustavo Gutierrez Gonzalez
Vrije Universiteit Brussel, Brussels, Belgium
Approved: 16 September 2013
 16 September 2013 Referee Report:
The authors have satisfactorily addressed all my previous comments. This is a very informative and
brilliantly written review on miRNAs and their current and potential use in human diseases' diagnosis and
therapy. I only have two more minor suggestions to finalize the review:
Page 3 of 14: When the authors cite and discuss reference 37 (Sempere .) the number '2' is  et al
missing from one of the HER2 genotypes they mentioned. Also, when looking to the original paper
published in 2007, I am not sure the authors refer to the right TMA genotypes, and their
conclusions seem a bit too vague: what does it mean that miR-145 shows an "opposite
pattern"? That statement is not that clear to me when I look at Figure 3 of the original paper.
Page 8 of 14: The authors talk about "heart generation" but it should read "heart regeneration". I
would suggest: "Upregulation of miR-15 and miR-195 executes a postnatal cell cycle arrest during
the process of heart regeneration after myocardial infarction (ref. 100)".
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed. Competing Interests:
Referee Responses for Version 1
  Gustavo Gutierrez Gonzalez
Vrije Universiteit Brussel, Brussels, Belgium
Approved: 24 June 2013
 24 June 2013 Referee Report:
Hydbring and Badalian-Very summarize in this review, the current status in the potential development of
clinical applications based on miRNAs’ biology. The article gives an interesting historical and scientific
perspective on a field that has only recently boomed; focusing mostly on the two main products in the
pipeline of several biotech companies (in Europe and USA) which work with miRNAs-based agents,
disease diagnostics and therapeutics. Interestingly, not only the specific agents that are being produced
are mentioned, but also clever insights in the important cellular pathways regulated by key miRNAs are
briefly discussed.
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briefly discussed.
Minor points to consider in subsequent versions:
Page 2; paragraph  the concept of miRNA  ‘Genomic location and transcription of microRNAs’:
clusters and precursors could be a bit better explained.
Page 2; paragraph   when discussing the paper ‘Genomic location and transcription of microRNAs’:
by the laboratory of Richard Young (reference 16); I think it is important to mention that that
particular study refers to stem cells.
Page 2; paragraph   “Argonate” should be replaced by “Argonaute”. ‘Processing of microRNAs’:
Page 3; paragraph   are miR-15a and 16-1 two different ‘MicroRNAs in disease diagnostics’:
miRNAs? I suggest mentioning them as: miR-15a and miR-16-1 and not using a slash sign (/)
between them.
Page 4; paragraph   I am a bit bothered by the description of multiple ‘Circulating microRNAs’:
sclerosis (MS) only as an autoimmune disease. Without being an expert in the field, I believe that
there are other hypotheses related to the etiology of MS.
Page 5; paragraph   Does ‘hsa’ in hsa-miR-205 mean something? ‘Clinical microRNA diagnostics’:
Page 5; paragraph   the authors mention the company Asuragen, ‘Clinical microRNA diagnostics’:
Austin, TX, USA but they do not really say anything about their products. I suggest to either remove
the reference to that company or to include their current pipeline efforts.
Page 6; paragraph   in the first paragraph the authors suggest that ‘MicroRNAs in therapeutics’:
miRNAs-based therapeutics should be able to be applied with “minimal side-effects”. Since one
miRNA can affect a whole gene program, I found this a bit counterintuitive; I was wondering if any
data has been published to support that statement. Also, in the same paragraph, the authors
compare miRNAs to protein inhibitors, which are described as more specific and/or selective. I
think there are now good indications to think that protein inhibitors are not always that specific
and/or selective and that such a property actually could be important for their evidenced
therapeutic effects.
Page 6; paragraph   I think the concept of “antagomir” is an important ‘MicroRNAs in therapeutics’:
one and could be better highlighted in the text.
Throughout the text (pages 3, 5, 6, and 7): I am a bit bothered by separating the word “miRNA” or
“miRNAs” at the end of a sentence in the following way: “miR-NA” or “miR-NAs”. It is a bit
confusing considering the particular nomenclature used for miRNAs. That was probably done
during the formatting and editing step of the paper.
I was wondering if the authors could develop a bit more the general concept that seems to indicate
that in disease (and in particular in cancer) the expression and levels of miRNAs are in general
downregulated. Maybe some papers have been published about this phenomenon?
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
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I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed. Competing Interests:
1 Comment
Author Response
, Dana-Farber Cancer Institute and Harvard Medical School, USA Per Hydbring
Posted: 15 Aug 2013
We thank reviewer Dr. Gustavo Gutierrez Gonzalez, for very valuable comments helping to
improve our manuscript. We have adjusted our text according to the comments from Dr. Gutierrez
Gonzalez. For clarification, we include a bullet-point response to each comment below.
In response to this comment we have added a few words in this paragraph. Further, we
added a sentence in the previous paragraph “MicroRNA discovery”.
We have clarified in this paragraph that the study refers to stem cells.
We thank the reviewer for pointing this out. This typo has been adjusted.
miR-15a and 16-1 originate from the same polycistronic transcript and have identical seed
sequences. However, as the reviewer point out, they are still two separate mature miRNAs.
We have therefore adjusted the text according to the reviewer’s suggestion to avoid
confusion.
We agree with the reviewer of this misleading description and have adjusted the text
accordingly.
This means “homo sapiens” but to avoid confusion we have removed it from miR-205.
In accordance to the reviewer’s suggestion we have removed this company reference.
Since there is currently only one miRNA drug in clinical trials, there is little direct evidence of
that miRNAs can be applied with minimal side-effects. In support of our hypothesis, their
mechanism of action is tuning expression rather than blunting their targets which reasonably
should be less detrimental to healthy tissues. We have added one sentence in this
paragraph to clarify our hypothesis. We further agree with the reviewer that a lot of
enzymatic protein inhibitors could be more selective. However, the purpose of these drugs
is selectivity. In contrast, miRNA drugs are developed with the idea of controlling multiple
gene-components in the same or overlapping signaling-pathways. Such gene-products are
not limited to proteins with enzymatic activity but could include any deregulated genes or
proteins in a given disease.
We agree with the reviewer and have made slight adjustments in the text to better highlight
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We agree with the reviewer and have made slight adjustments in the text to better highlight
this concept.
This has been an editing/formatting mistake. In our original manuscript there are no
separations of the word “miRNA” or “miRNAs”.
We describe downregulation of miRNAs in the section “MicroRNAs in disease diagnostics”
referring to a few publications (25, 35-39). To better clarify a general impact of reduced
miRNA expression in cancers we included an additional reference (40), describing a
conditional knockout mice model for miRNA biogenesis leading to reduced survival in
affected mice.
 No competing interests were disclosed. Competing Interests:
  Florian Karreth
Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA
Approved: 18 June 2013
 18 June 2013 Referee Report:
This review article by Hydbring and Badalian-Very summarizes our current knowledge of microRNAs and
outlines their clinical value. The authors provide a comprehensive overview of microRNA biology and
target prediction and discuss the utility of miRNAs as prognostic and diagnostic markers and therapeutic
targets. Finally, Hydbring and Badalian-Very highlight the various strategies adopted by leading
biotechnology companies and the state of their current clinical trials. 
I have two minor suggestions regarding the biology of miRNAs that the authors may wish to include in
their manuscript: 
A recent paper by paper by Tollervey and colleagues ( ) describes that a Helwak  ., Cell 2013 et al
large fraction of miRNAs bind their targets independent of seed match complementarity at
nucleotides 2-7. This observation greatly affects our ability to accurately predict miRNA targets
using existing algorithms.
Besides the 3’UTR, miRNAs have been demonstrated to target the 5’UTR and coding sequence of
mRNAs as well as other RNA species such as lncRNAs, pseudogenes, rRNAs and tRNAs.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed. Competing Interests:
1 Comment
Author Response
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, Dana-Farber Cancer Institute and Harvard Medical School, USA Per Hydbring
Posted: 15 Aug 2013
We thank reviewer Dr. Florian Karreth for very valuable comments helping to improve our
manuscript. We have adjusted our text according to the comments from Dr. Karreth. For
clarification, we include a bullet-point response to each comment below.
We thank the reviewer for pointing out this paper which brings the understanding of
microRNA targeting to a higher level. We have included this reference and commented on it
in the text (paragraph “MicroRNA functional targeting”).
The reviewer makes a very important point and to cover some of these mechanisms we
have added three references and commented shortly on them in the text (paragraph
“MicroRNA functional targeting”). However, since our main focus is on the clinical aspects of
microRNAs we believe a deeper description of non-canonical microRNA targeting is out of
scope for this review.
 No competing interests were disclosed. Competing Interests:
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